These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 18758941)

  • 1. Hyponatremia in heart failure.
    Farmakis D; Filippatos G; Parissis J; Kremastinos DT; Gheorghiade M
    Heart Fail Rev; 2009 Jun; 14(2):59-63. PubMed ID: 18758941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Introduction: Vasopressin therapy.
    Whellan DJ
    Heart Fail Rev; 2009 Jun; 14(2):57-8. PubMed ID: 18989773
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of hypervolemic or euvolemic hyponatremia associated with heart failure, cirrhosis, or the syndrome of inappropriate antidiuretic hormone with tolvaptan: a clinical review.
    Nemerovski C; Hutchinson DJ
    Clin Ther; 2010 Jun; 32(6):1015-32. PubMed ID: 20637957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum and urine responses to the aquaretic agent tolvaptan in hospitalized hyponatremic patients.
    Vaghasiya RP; DeVita MV; Michelis MF
    Int Urol Nephrol; 2012 Jun; 44(3):865-71. PubMed ID: 21607553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyponatremia in acute decompensated heart failure: mechanisms, prognosis, and treatment options.
    Jao GT; Chiong JR
    Clin Cardiol; 2010 Nov; 33(11):666-71. PubMed ID: 21089110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of serum sodium concentration and tolvaptan treatment on length of hospitalization in patients with heart failure.
    Cyr PL; Slawsky KA; Olchanski N; Krasa HB; Goss TF; Zimmer C; Hauptman PJ
    Am J Health Syst Pharm; 2011 Feb; 68(4):328-33. PubMed ID: 21289328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correction of hyponatremia by tolvaptan before left ventricular assist device implantation.
    Imamura T; Kinugawa K; Shiga T; Kato N; Endo M; Inaba T; Maki H; Hatano M; Yao A; Hirata Y; Nishimura T; Kyo S; Ono M; Nagai R
    Int Heart J; 2012; 53(6):391-3. PubMed ID: 23258142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Etiology, diagnostics and therapy of hyponatremias].
    Laczi F
    Orv Hetil; 2008 Jul; 149(29):1347-54. PubMed ID: 18617466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of tolvaptan in patients hospitalized for worsening chronic heart failure with severe hyponatremia: The initial experience at a single-center in Turkey.
    Sağ S; Aydın Kaderli A; Yıldız A; Gül BC; Özdemir B; Baran İ; Güllülü S; Aydınlar A; Çavuşoğlu Y
    Turk Kardiyol Dern Ars; 2017 Jul; 45(5):415-425. PubMed ID: 28694395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AVP receptor antagonists in patients with CHF.
    Kumar SK; Mather PJ
    Heart Fail Rev; 2009 Jun; 14(2):83-6. PubMed ID: 18766439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyponatremia, heart failure, and the role of tolvaptan.
    O'Connell JB; Alemayehu A
    Postgrad Med; 2012 Mar; 124(2):29-39. PubMed ID: 22437213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia.
    Schrier RW; Gross P; Gheorghiade M; Berl T; Verbalis JG; Czerwiec FS; Orlandi C;
    N Engl J Med; 2006 Nov; 355(20):2099-112. PubMed ID: 17105757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Vasopressin antagonists in treatment of hyponatremia].
    Olszewski W; Głuszek J
    Pol Arch Med Wewn; 2007 Aug; 117(8):356-62. PubMed ID: 18018383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of tolvaptan for euvolemic or hypervolemic hyponatremia.
    Lee MY; Kang HJ; Park SY; Kim HL; Han E; Lee EK
    Clin Ther; 2014 Sep; 36(9):1183-94. PubMed ID: 25151571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of tolvaptan in patients hospitalized for heart failure with refractory hyponatremia. Clinical experience in daily practice.
    Salterain-Gonzalez N; Esteban-Fernández A; García-López M; Lavilla-Royo FJ; Gavira-Gómez JJ
    Rev Esp Cardiol (Engl Ed); 2013 Jun; 66(6):503-4. PubMed ID: 24776057
    [No Abstract]   [Full Text] [Related]  

  • 16. Vasopressin and vasopressin antagonists in heart failure and hyponatremia.
    Farmakis D; Filippatos G; Kremastinos DT; Gheorghiade M
    Curr Heart Fail Rep; 2008 Jun; 5(2):91-6. PubMed ID: 18765079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of tolvaptan on acute heart failure with hyponatremia--a randomized, double blind, controlled clinical trial.
    Shanmugam E; Doss CR; George M; Jena A; Rajaram M; Ramaraj B; Anjaneyan K; Kanagesh B
    Indian Heart J; 2016 Apr; 68 Suppl 1(Suppl 1):S15-21. PubMed ID: 27056648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment options for hyponatremia in heart failure.
    Goldsmith SR
    Heart Fail Rev; 2009 Jun; 14(2):65-73. PubMed ID: 18777208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vasopressin receptor antagonists.
    Greenberg A; Verbalis JG
    Kidney Int; 2006 Jun; 69(12):2124-30. PubMed ID: 16672911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical review: the use of vaptans in clinical endocrinology.
    Peri A
    J Clin Endocrinol Metab; 2013 Apr; 98(4):1321-32. PubMed ID: 23401044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.